Rejoni Raises $25M in Funding Round by Clavyst Bio

The company plans to use the funding to expand its operations and continue developing its products and technology.

Juveena is designed to help the uterus heal after intrauterine surgery, which can sometimes lead to the formation of intrauterine adhesions. The treatment supports recovery of the uterine lining following surgical procedures.

Read More:Ent Raises $100M in Seed Funding Led by Decibel

Rejoni plans to expand its manufacturing and supply capabilities, invest in market access and education for physicians and patients, and prepare for the commercial launch of Juveena if it receives approval from the U.S. Food and Drug Administration (FDA).

“Uterine health has been underserved for too long, and this financing puts us in a position to change that. We are building the infrastructure, commercial readiness, market access, and physician engagement to ensure we can move quickly when Juveena is approved,” said John Nealon, Chief Executive Officer of Rejoni, Inc.

“This financing marks an important milestone in Rejoni’s evolution from building the science to preparing for launch. John and the team have the experience and drive to execute on this opportunity, and I remain fully committed to this mission,” said Amar Sawhney, Founder and Chairman of Rejoni, Inc.

About Rejoni, Inc.

Founded in 2020 and based in Bedford, Massachusetts, Rejoni is a clinical-stage biotechnology company focused on developing and commercializing womens health products. The company uses its proprietary biomaterials technology to create innovative gynecological solution's aimed at improving patient outcomes.

Read More:Traysar Raises $25M in Seed Funding Led by Silent Ventures